Celgene Corporation (CELG)

[rmjackson]

Next years valuation
Looking at the numbers for next year, we sit at $5.95. That would put us at $148.75 for next year. I think this VRX ordeal could cause a retest of the lows again for biotech. I know I am waiting for that opportunity should we get it. I am a buyer at and below $110. I still see 28 to 30B in long term peak sales for this current pipeline. Right now we have Revlimid, Abraxane, Pomalyst and Otezla to drive earnings out to 2018 and 2019 when we would see Morgesen and Ozanimod reach the market.